James F. Barlow - Aug 1, 2023 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Role
Director
Signature
/s/ Ilan Katz, attorney-in-fact
Stock symbol
ARCT
Transactions as of
Aug 1, 2023
Transactions value $
$0
Form type
4
Date filed
8/3/2023, 04:10 PM
Previous filing
Jun 27, 2022
Next filing
Jun 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARCT Stock option (right to buy) Award $0 +11.9K $0.00 11.9K Aug 1, 2023 Common Stock 11.9K $34.92 Direct F1
transaction ARCT Deferred Stock Units Award $0 +3.13K $0.00 3.13K Aug 1, 2023 Common Stock 3.13K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
F2 Each deferred stock unit is economically equivalent to one share of the Issuer's common stock.
F3 Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.